Department of Pharmacy, The Methodist Hospital The Kidney Institute, Houston, TX, USA.
Clin Transplant. 2010 Nov-Dec;24(6):E253-6. doi: 10.1111/j.1399-0012.2010.01297.x.
Cardiovascular disease is the leading cause of death in renal transplant patients. This study compares the use of cardioprotective medications in adult kidney transplant recipients at a single center with recommendations, which have been validated in the general population. Cardioprotective medication use was retrospectively collected post-renal transplant. Patients were defined as high risk if they had pre-transplant coronary heart disease or equivalent risk. "Optimal" treatment was defined as a patient receiving aspirin, statin, angiotensin-converting enzyme inhibitors/angiotensin receptor blocker, and a beta-blocker according to cardiovascular risk. The percentage of high-risk patients optimally treated at one, three, six, and 12 months was 7.7%, 11.5%, 17.6%, and 18.8%, respectively. Although the use of cardioprotective medications was evident in transplant recipients, opportunities exist to increase the use of optimal cardioprotective regimens after renal transplantation.
心血管疾病是肾移植患者的主要死亡原因。本研究比较了单中心成人肾移植受者使用心脏保护药物的情况，并与已在普通人群中验证的建议进行了比较。心脏保护药物的使用是在肾移植后回顾性收集的。如果患者在移植前患有冠心病或具有同等风险，则将其定义为高危。“最佳”治疗定义为根据心血管风险，患者接受阿司匹林、他汀类药物、血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂和β受体阻滞剂。在 1、3、6 和 12 个月时，高危患者接受最佳治疗的百分比分别为 7.7%、11.5%、17.6%和 18.8%。尽管心脏保护药物在移植受者中得到了广泛应用，但在肾移植后仍有机会增加最佳心脏保护方案的使用。
